A primigravida was referred with hyperthyroidism in early pregnancy from longstanding Graves' disease treated with propylthiouracil. She had selective elevation of free tri-iodothyronine (fT3) levels, low normal free tetra-iodothyronine (fT4) and suppressed thyroid-stimulating hormone (TSH). Given her symptoms of thyrotoxicosis and elevated TSH receptor antibodies, therapy was tailored towards maintaining clinical and biochemical euthyroidism. However the fetus developed a goitre secondary to hypothyroidism. This case highlights the dilemmas in managing maternal T3 toxicosis while aiming for a high normal fT4 to prevent fetal hypothyroidism including the role of fetal ultrasound monitoring and amniocentesis.
INTRODUCTION
Fetal and neonatal thyroid disturbances are well described in association with maternal Graves' disease. 1 The most common disturbances are neonatal thyrotoxicosis induced by thyrotropin receptor-stimulating antibodies and hypothyroidism from maternal antithyroid drugs or thyrotropin receptor inhibiting antibodies (TRiAbs) which bind to the thyroid-stimulating hormone (TSH) receptor and prevent TSH action. 1, 2 We describe an unusual case of maternal tri-iodothyronine (T3) toxicosis with neonatal hypothyroidism.
CASE
A 32-year-old primigravida was referred to our centre at seven weeks gestation, with a 15-year history of Graves' disease for which she had refused definitive treatment. At presentation she was clinically hyperthyroid with tachycardia, tremors and a prominent goitre with an audible bruit, but no ophthalmopathy. She was taking 50 mg propylthiouracil (PTU) thrice daily. The thyroid function tests (TFTs) suggested T3 toxicosis with free T4 (fT4) of 7 nmol/L, free T3 (fT3) of 11.8 pmol/L and TSH , 0.01 mU/L ( Table 1) . She had an admission for threatened miscarriage at nine weeks gestation. Maternal TSH receptor antibodies (TRAbs) were positive at 14 IU/L. At 27 weeks, the TFT results improved (Table 1 ) and the PTU dose was reduced to 50 mg twice daily.
However, an obstetric ultrasound at 32 weeks demonstrated a normally grown fetus with a goitre ( Figure 1 ) with a thyroid circumference (TC) of 82 mm (.95th centile). There were no other ultrasound features to suggest fetal hypothyroidism or hyperthyroidism. Maternal hyperthyroidism had recurred with symptoms and marginal increase in T3 (Table 1) at this time and hence the PTU was increased to 50 mg thrice daily. However the progress scan at 34 weeks revealed an increase in size of the fetal thyroid (TC 92 mm) and absence of distal femoral ossification now suggesting fetal hypothyroidism. Invasive testing was recommended and since the mother refused cord blood sampling, amniocentesis was performed. The amniotic fluid TSH level was 1.93 (0.1-0.5) mU/L and fT4 was 10 (5.1-9.0) pmol/L. These results were consistent with fetal hypothyroidism and hence PTU was decreased to 50 mg daily. A 36 weeks maternal scan revealed a decrease in goitre size (TC 72 mm) amniotic fluid TSH level had improved (TSH 0.19).
Fetal distress with bradycardia was identified at a routine 37 weeks follow-up scan, resulting in an emergency caesarean section with uncomplicated maternal recovery. The neonate was delivered with a birth weight of 3.3 kg and APGAR scores of 5 and 9 at one and five minutes, respectively. A metabolic acidaemia was reported on the cord gases and the baby was admitted to the neonatal intensive care unit. No goitre was noted on clinical examination. At four hours of age, the neonatal TSH was 182 with fT4 of 13.7 (12 -36) pmol/L. Thyroxine replacement was commenced at 10 mg/kg and neonatal TFT improved back into normal range after one week of therapy. Thyroxine was discontinued at three months with normal development milestones over the next 12 months. Maternal hyperthyroidism recurred at the six week follow-up visit requiring increased PTU doses. This was subsequently changed to carbimazole at a current dose of 10 mg daily.
DISCUSSION
Graves' disease occurs in approximately 0.1-0.4% of pregnancies and the current guidelines recommend treating maternal hyperthyroidism to keep the fT4 in the upper third of the reference range. 1 It is also known that fetal thyroid function correlates with maternal fT4 rather than the dose of antithyroid drugs (ATDs). 3 However, to the best of our knowledge, there are no guidelines or literature on managing T3 toxicosis in pregnancy.
Our patient had clinical thyrotoxicosis with elevated free T3, significantly raised TRAbs and a threatened miscarriage in early pregnancy, despite a low normal fT4. The TFTs improved in late second trimester as is usually the case permitting a dose reduction of PTU. Recurrence of maternal hyperthyroid symptoms and detection of the fetal goitre at 32 weeks were suspicious for fetal thyrotoxicosis. Moreover, maternal TRAbs of greater than 5 IU/L seem to have a 100% sensitivity and 76% specificity for neonatal thyrotoxicosis independent of maternal thyroid function. 4 Ultrasound scores based on fetal heart rate, movements, bone maturation and Doppler vascularization of the fetal goitre may help to differentiate fetal hypothyroidism from thyrotoxicosis and there have been attempts to standardize these findings. 5, 6 These features were unfortunately not evident on our initial scan at 32 weeks, confusing the decision further. However, later detection of delayed ossification of the distal femoral epiphysis coupled with increase in goitre size after increased PTU suggested fetal hypothyroidism.
Although fetal blood sampling is the gold standard to assess fetal thyroid status, amniotic fluid sampling has been shown to be useful for detecting fetal hypothyroidism. 7 Reducing the dose of ATDs is the initial step in treatment and if this does not suffice then intra-amniotic thyroxine can be administered with benefit as evidenced by case reports in literature. 8, 9 Despite the improvement in the goitre and amniotic fluid TSH, the baby experienced severe bradycardia warranting emergency delivery. There was no evidence of abruption or other pathology of the maternal -fetal placental unit to explain this event. The elevated TSH at birth is difficult to interpret in the context of fetal distress with bradycardia and therefore an exaggerated TSH surge in the first 24-48 hours after birth. 10 Nevertheless, treatment with thyroxine was prudent to avoid the consequences of neonatal hypothyroidism. It is also encouraging to note that the baby has developed with normal milestones and only required three months of thyroxine replacement suggesting the hypothyroidism was transient.
The risks for fetal hypothyroidism in our case were the low normal maternal fT4, but more so the use of antithyroid drugs. It is known that the affinity of the thyroid hormone transporters expressed in the placenta is similar for free T4 and free T3, except for MCT 10 and LAT1, which have higher affinity for T3. However the deiodinase enzyme D3 which inactivates T4 and T3 to rT3/T2 by inner ring deiodination, has much greater expression and activity in the placenta and D3 has a higher affinity for free T3. Thus T3 may preferentially be prevented from reaching the fetus as a protective measure in normal physiology. 11 Therefore, the elevated fT3 will not compensate for the low fT4.
Given the maternal thyrotoxicosis, TRiAb was less likely to be responsible. It appears that aiming for high normal fT4 levels despite elevated fT3 may have fetal benefits in reducing the risk of hypothyroidism, though this needs to be weighed against the risk of continuation of the pregnancy as in our case. The recent American thyroid association (ATA) guidelines recommend against routinely measuring T3 during pregnancy and to avoid aiming for normal T3 levels given the associated risk of elevated fetal TSH at birth, but T3 toxicosis is mentioned 
